Celon Pharma (LTS:0RKX) Valuation Rank


LTS:0RKX Celon Pharma SA LTS:0RKX
48 GF Score
Price zł22.50
GF Value zł26.17
! 3 Warning Signs
View Full Analysis

What is Celon Pharma Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Celon Pharma Valuation Rank Related Terms

LTS:0RKX
48GF Score
Celon Pharma SA LTS:0RKX
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Celon Pharma (LTS:0RKX) Overvalued in 2026?

Based on GuruFocus' analysis, Celon Pharma stock appears to be undervalued. The current stock price of zł22.50 is trading 14% below its estimated GF Value™ of zł26.17.

Key valuation signals for LTS:0RKX:

  • Valuation Rank:
  • GF Value™: zł26.17 vs. price of zł22.50 (14% below fair value)
  • GF Score™: 48/100 with 3 warning signs

No single metric tells the full story. See the LTS:0RKX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celon Pharma Business Description

Other Exchanges CLN:Poland8RP:Germany
Address Ogrodowa 2A, Kielpin, Lomianki, POL, 05-092
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
48GF Score

Get the complete analysis for LTS:0RKX

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł22.50
Price
zł26.17
GF Value